Pfizer Inc. reported solid second-quarter 2018 financial results, with total company revenues up two percent operationally.

Amgen Inc.’s push to get patients on its new $575 a month migraine drug before competition emerges in September 2018 is facing barriers from insurers.

The Wall Street Journal reported that Pfizer increased the list prices for more than 40 of the pharma giant’s prescribed medications.

As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.